{"protocolSection": {"identificationModule": {"nctId": "NCT00545272", "orgStudyIdInfo": {"id": "CQMF149A2201"}, "secondaryIdInfos": [{"id": "2007-003191-19", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER\u00ae Device in Adult and Adolescent Patients With Persistent Asthma", "officialTitle": "A Randomized, Multi-center, Parallel Group, Double Blind, Placebo and Formoterol Controlled 14 Day Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER\u00ae Device in Adult and Adolescent Patients With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2012-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-10"}, "primaryCompletionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-16", "studyFirstSubmitQcDate": "2007-10-16", "studyFirstPostDateStruct": {"date": "2007-10-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-11-12", "resultsFirstSubmitQcDate": "2012-12-12", "resultsFirstPostDateStruct": {"date": "2013-01-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-12-12", "lastUpdatePostDateStruct": {"date": "2013-01-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}, "collaborators": [{"name": "Schering-Plough", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "This study will evaluate the dose response relationship among four doses of indacaterol as well as placebo delivered via the TWISTHALER\u00ae device."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["QMF", "indacaterol", "Twisthaler\u00ae"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 392, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "indacaterol 62.5 \u03bcg", "type": "EXPERIMENTAL", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.", "interventionNames": ["Drug: indacaterol", "Drug: placebo to formoterol", "Drug: short acting \u03b22-agonist"]}, {"label": "indacaterol 125 \u03bcg", "type": "EXPERIMENTAL", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.", "interventionNames": ["Drug: indacaterol", "Drug: placebo to formoterol", "Drug: short acting \u03b22-agonist"]}, {"label": "indacaterol 250 \u03bcg", "type": "EXPERIMENTAL", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.", "interventionNames": ["Drug: indacaterol", "Drug: placebo to formoterol", "Drug: short acting \u03b22-agonist"]}, {"label": "indacaterol 500 \u03bcg", "type": "EXPERIMENTAL", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.", "interventionNames": ["Drug: indacaterol", "Drug: placebo to formoterol", "Drug: short acting \u03b22-agonist"]}, {"label": "formoterol", "type": "ACTIVE_COMPARATOR", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.", "interventionNames": ["Drug: formoterol", "Drug: placebo to indacaterol", "Drug: short acting \u03b22-agonist"]}, {"label": "placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.", "interventionNames": ["Drug: placebo to indacaterol", "Drug: placebo to formoterol", "Drug: short acting \u03b22-agonist"]}], "interventions": [{"type": "DRUG", "name": "indacaterol", "description": "Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER\u00ae device).", "armGroupLabels": ["indacaterol 125 \u03bcg", "indacaterol 250 \u03bcg", "indacaterol 500 \u03bcg", "indacaterol 62.5 \u03bcg"]}, {"type": "DRUG", "name": "formoterol", "description": "Formoterol delivered by oral inhalation via AEROLIZER\u00ae inhalation device.", "armGroupLabels": ["formoterol"]}, {"type": "DRUG", "name": "placebo to indacaterol", "description": "Placebo TWISTHALER\u00ae device", "armGroupLabels": ["formoterol", "placebo"]}, {"type": "DRUG", "name": "placebo to formoterol", "description": "Placebo AEROLIZER\u00ae device", "armGroupLabels": ["indacaterol 125 \u03bcg", "indacaterol 250 \u03bcg", "indacaterol 500 \u03bcg", "indacaterol 62.5 \u03bcg", "placebo"]}, {"type": "DRUG", "name": "short acting \u03b22-agonist", "description": "100 \u03bcg/ 90 \u03bcg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).", "armGroupLabels": ["formoterol", "indacaterol 125 \u03bcg", "indacaterol 250 \u03bcg", "indacaterol 500 \u03bcg", "indacaterol 62.5 \u03bcg", "placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 14 days of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.", "timeFrame": "Baseline (prior to first dose) and Day 15 (24 hours after last dose)"}], "secondaryOutcomes": [{"measure": "Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose", "description": "FEV1 was measured on Day 14 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.", "timeFrame": "Day 14, pre-dose, 5, 20 and 30 minutes, 1, 2, 3, and 4 hours post-dose."}, {"measure": "The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) on Day 1", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 1 day of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.", "timeFrame": "Day 1 Baseline (prior to first dose) and 24 hours post-dose."}, {"measure": "Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose on Day 1", "description": "FEV1 was measured on Day 1 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.", "timeFrame": "Day 1, pre-dose, 5, 20 and 30 minutes, 1, 2, 3, and 4 hours post-dose."}, {"measure": "Time to Peak Forced Expiratory Volume in 1 Second (FEV1) on Day 1 and Day 14", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Time to peak FEV1 is calculated in minutes from the time of inhalation of study drug to the time of the peak FEV1, which is taken as the maximum FEV1 recorded post-dose.", "timeFrame": "Day 1 and Day 14 measured pre-dose and up to 4 hours post-dose"}, {"measure": "Change From Baseline in Morning and Evening Peak Expiratory Flow", "description": "The Peak Expiratory Flow (PEF) rate is the maximal rate that a person can exhale during a short maximal expiratory effort after fully inhaling. Participants measured their PEF using a peak flow meter and recorded measurements in a diary every morning and evening during the study, prior to taking study medication. Change from baseline is the difference between the mean baseline PEF recorded during the screening period until the first day of treatment, and the overall mean PEF from Days 1 to 14.", "timeFrame": "Baseline (recorded during the screening period) and Days 1-14 (treatment period)"}, {"measure": "Number of Participants Using Rescue Medication", "description": "Participants recorded the use of rescue medications (salbutamol/albuterol) for treatment of asthma symptoms twice a day in a diary during the 14 days of the treatment period.", "timeFrame": "Over 14 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female adult and adolescent patients aged 12-75 years inclusive (or \u226518-75 years depending upon regulatory and/or Institutional Review Board (IRB)/Independent Ethics Committee (IEC)/Research Ethics Board (REB) approval), who have signed an Informed Consent Form prior to initiation of any study-related procedure, including any adjustments to asthma medication prior to Visit 1. Patients below the legal age of consent are required to have the Informed Consent Form signed by the patient's parent / guardian.\n2. Patients with asthma, diagnosed according to Global Initiative for Asthma (GINA) guidelines (National Institute of Health, National Heart, Lung and Blood Institute, 2006) and who additionally meet the following criteria:\n\n   1. Patients receiving daily treatment with inhaled corticosteroid up to the maximum dose per day indicated in the package leaflet, in a stable regimen for the month prior to Visit 1.\n   2. Patients with a Forced Expiratory Volume in one second (FEV1) at Visit 1 of \u226550% of the predicted normal value for the patient. This criterion for FEV1 will have to be demonstrated after a washout period of at least 6 hours during which no short acting \u03b22-agonist has been inhaled, and a minimum of 48 hours for a long acting \u03b22-agonist.\n   3. Patients who demonstrate an increase of \u226512% and \u2265200 mL in FEV1 over their pre-bronchodilator value within 30 minutes after inhaling a total of 200 \u00b5g/180 \u00b5g of salbutamol/albuterol Metered Dose Inhaler (MDI) (or equivalent dose of Dry Powder Inhaler \\[DPI\\]) (the reversibility test). Reversibility will have to be demonstrated after an appropriate washout period of at least 6 hrs prior to the evaluation for a short-acting \u03b22-agonist. The administration of salbutamol/albuterol for the reversibility test is to be within 30 minutes after pre bronchodilator spirometry. Reversibility has to be demonstrated at Visit 1 or between Visits 1 and 2, in order for patients to be included in the trial.\n\nExclusion Criteria:\n\n* Pregnant women, nursing mothers, or females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception.\n* Patients with Chronic Obstructive Pulmonary Disease (COPD), or current smokers, or patients who have used tobacco products within the 6 month period prior to Visit 1, or who have a smoking history of greater than 10 pack years.\n* Patients:\n\n  1. who's asthma is likely to deteriorate during the study (including seasonal allergy),\n  2. hospitalized for an acute asthma attack/asthma exacerbation within 6 months prior to Visit 1,\n  3. who have had an emergency room visit for an asthma attack/asthma exacerbation within 6 weeks prior to Visit 1\n  4. who have had a respiratory tract infection or emergency room treatment for an asthma attack/asthma exacerbation within 4 weeks prior to Visit 1\n  5. Patients who require the use of \u22658 inhalations per day of short acting B2-agonist (100 \u00b5g/ 90 \u00b5g salbutamol/albuterol MDI or equivalent dose of DPI) on any 2 consecutive days from Screening to Randomization.\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharma", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Novartis Investigator Site", "city": "Aalst", "country": "Belgium", "geoPoint": {"lat": 50.93604, "lon": 4.0355}}, {"facility": "Novartis Investigator Site", "city": "Halen", "country": "Belgium", "geoPoint": {"lat": 50.94837, "lon": 5.11096}}, {"facility": "Novartis Investigator Site", "city": "Oostham", "country": "Belgium", "geoPoint": {"lat": 51.10374, "lon": 5.17877}}, {"facility": "Novartis Investigator site", "city": "Veurne", "country": "Belgium", "geoPoint": {"lat": 51.07316, "lon": 2.66803}}, {"facility": "Novartis Investigator Site", "city": "Boskovice", "country": "Czech Republic", "geoPoint": {"lat": 49.48751, "lon": 16.65997}}, {"facility": "Novartis Investigator site", "city": "Breclav", "country": "Czech Republic", "geoPoint": {"lat": 48.75897, "lon": 16.88203}}, {"facility": "Novartis Investigator Site", "city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "Novartis Investigator Site", "city": "Liberec", "country": "Czech Republic", "geoPoint": {"lat": 50.76711, "lon": 15.05619}}, {"facility": "Novartis Investigator Site", "city": "Most", "country": "Czech Republic", "geoPoint": {"lat": 50.50301, "lon": 13.63617}}, {"facility": "Novartis Investigator Site", "city": "Tabor", "country": "Czech Republic", "geoPoint": {"lat": 49.41441, "lon": 14.6578}}, {"facility": "Novartis Investigator Site", "city": "Aalen", "country": "Germany", "geoPoint": {"lat": 48.83777, "lon": 10.0933}}, {"facility": "Novartis Investigator Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigator Site", "city": "Braunschweig", "country": "Germany", "geoPoint": {"lat": 52.26594, "lon": 10.52673}}, {"facility": "Novartis Investigator Site", "city": "Deggendorf", "country": "Germany", "geoPoint": {"lat": 48.84085, "lon": 12.96068}}, {"facility": "Novartis Investigator Site", "city": "Furstenwalde", "country": "Germany", "geoPoint": {"lat": 52.36067, "lon": 14.06185}}, {"facility": "Novartis Investigator Site", "city": "Leipzig", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "novartis Investigator site", "city": "Munchen", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Novartis investigator site", "city": "Balassagyarmat", "country": "Hungary", "geoPoint": {"lat": 48.07296, "lon": 19.29614}}, {"facility": "Novartis Investigator Site", "city": "Erd", "country": "Hungary", "geoPoint": {"lat": 47.39489, "lon": 18.91361}}, {"facility": "Novartis Investigator site", "city": "Fuzesabony", "country": "Hungary", "geoPoint": {"lat": 47.75, "lon": 20.41667}}, {"facility": "Novartis Investigator Site", "city": "Gyonggyos", "country": "Hungary"}, {"facility": "Novartis Investigator Site", "city": "Mosdoz", "country": "Hungary"}, {"facility": "Novartis Investigator Site", "city": "Pest", "country": "Hungary", "geoPoint": {"lat": 47.5, "lon": 19.08333}}, {"facility": "Novartis Investigator Site", "city": "Siofok", "country": "Hungary", "geoPoint": {"lat": 46.90413, "lon": 18.058}}, {"facility": "Novartis Investigator Site", "city": "Szazhalombatta", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Novartis Investigator Site", "city": "Afula", "country": "Israel", "geoPoint": {"lat": 32.60907, "lon": 35.2892}}, {"facility": "Novartis Investigator Site", "city": "Ashkelon", "country": "Israel", "geoPoint": {"lat": 31.66926, "lon": 34.57149}}, {"facility": "Novartis Investigator Site", "city": "Beer Sheva", "country": "Israel", "geoPoint": {"lat": 31.25181, "lon": 34.7913}}, {"facility": "Novartis investigator site", "city": "Haifa", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "Novartis investigator site", "city": "Jerusalem", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "Novartis Investigator Site", "city": "Petach Tikva", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "Novartis Investigator Site", "city": "Rehovot", "country": "Israel", "geoPoint": {"lat": 31.89421, "lon": 34.81199}}, {"facility": "Novartis Investigator Site", "city": "Tel Aviv", "country": "Israel", "geoPoint": {"lat": 32.08088, "lon": 34.78057}}, {"facility": "Novartis Investigator Site", "city": "Tel-Hashorner", "country": "Israel"}, {"facility": "Novartis Investigator Site", "city": "Zrifin", "country": "Israel", "geoPoint": {"lat": 31.95857, "lon": 4.83723}}, {"facility": "Novartis Investigator Site", "city": "Bialystok", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Novartis investigator site", "city": "Bydgoszcz", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Novartis Investigator Site", "city": "Lodz", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Novartis Investigator site", "city": "Lubin", "country": "Poland", "geoPoint": {"lat": 51.40089, "lon": 16.20149}}, {"facility": "Novartis Investigator Site", "city": "Tarnow", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Novartis Investigator Site", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Novartis Investigator Site", "city": "Saint-Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Novartis Investigator Site", "city": "Smolensk", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Novartis investigator site", "city": "Tomsk", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "Novartis Investigator Site", "city": "Bloernfontain", "country": "South Africa"}, {"facility": "Novartis Investigator Site", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Novartis Investigator Site", "city": "Johannesburg", "country": "South Africa", "geoPoint": {"lat": -26.20227, "lon": 28.04363}}, {"facility": "Novartis Investigator Site", "city": "Krugersdorp", "country": "South Africa", "geoPoint": {"lat": -26.08577, "lon": 27.77515}}, {"facility": "Novartis Investigator Site", "city": "les Marais", "country": "South Africa"}, {"facility": "Novartis Investigator Site", "city": "Pretoria", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Novartis Investigator Site", "city": "Roodepoort", "country": "South Africa", "geoPoint": {"lat": -26.1625, "lon": 27.8725}}, {"facility": "Novartis Investigator Site", "city": "Temba", "country": "South Africa", "geoPoint": {"lat": -25.38171, "lon": 28.26438}}, {"facility": "Novartis Investigator Site", "city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novartis Investigator Site", "city": "Pozuelo de Alacron", "country": "Spain"}, {"facility": "Novartis Investigator Site", "city": "Valencia", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Novartis Investigator Site", "city": "Downpatrick", "country": "United Kingdom", "geoPoint": {"lat": 54.32814, "lon": -5.71529}}, {"facility": "Novartis Investigator Site", "city": "Glasgow", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Novartis Investigator Site", "city": "London", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Novartis Investigator Site", "city": "Southampton", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}, {"facility": "Novartis Investigator Site", "city": "Watford", "country": "United Kingdom", "geoPoint": {"lat": 51.65531, "lon": -0.39602}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "FG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "FG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "FG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "FG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days."}, {"id": "FG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "61"}, {"groupId": "FG001", "numSubjects": "68"}, {"groupId": "FG002", "numSubjects": "65"}, {"groupId": "FG003", "numSubjects": "72"}, {"groupId": "FG004", "numSubjects": "64"}, {"groupId": "FG005", "numSubjects": "62"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "61"}, {"groupId": "FG001", "numSubjects": "67"}, {"groupId": "FG002", "numSubjects": "64"}, {"groupId": "FG003", "numSubjects": "71"}, {"groupId": "FG004", "numSubjects": "62"}, {"groupId": "FG005", "numSubjects": "59"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "BG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "BG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "BG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "BG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days."}, {"id": "BG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "BG006", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "68"}, {"groupId": "BG002", "value": "65"}, {"groupId": "BG003", "value": "72"}, {"groupId": "BG004", "value": "64"}, {"groupId": "BG005", "value": "62"}, {"groupId": "BG006", "value": "392"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41.3", "spread": "16.27"}, {"groupId": "BG001", "value": "38.4", "spread": "17.25"}, {"groupId": "BG002", "value": "36.6", "spread": "15.76"}, {"groupId": "BG003", "value": "40.1", "spread": "15.47"}, {"groupId": "BG004", "value": "44.0", "spread": "17.98"}, {"groupId": "BG005", "value": "39.8", "spread": "15.82"}, {"groupId": "BG006", "value": "40.0", "spread": "16.50"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "36"}, {"groupId": "BG003", "value": "39"}, {"groupId": "BG004", "value": "27"}, {"groupId": "BG005", "value": "37"}, {"groupId": "BG006", "value": "204"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "29"}, {"groupId": "BG003", "value": "33"}, {"groupId": "BG004", "value": "37"}, {"groupId": "BG005", "value": "25"}, {"groupId": "BG006", "value": "188"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1)", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 14 days of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.", "populationDescription": "The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. The analysis only includes patients with non-missing data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Baseline (prior to first dose) and Day 15 (24 hours after last dose)", "groups": [{"id": "OG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days."}, {"id": "OG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "67"}, {"groupId": "OG002", "value": "63"}, {"groupId": "OG003", "value": "68"}, {"groupId": "OG004", "value": "62"}, {"groupId": "OG005", "value": "58"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.039", "spread": "0.0408"}, {"groupId": "OG001", "value": "0.054", "spread": "0.0383"}, {"groupId": "OG002", "value": "0.124", "spread": "0.0401"}, {"groupId": "OG003", "value": "0.166", "spread": "0.0381"}, {"groupId": "OG004", "value": "0.075", "spread": "0.0405"}, {"groupId": "OG005", "value": "-0.018", "spread": "0.0415"}]}]}]}, {"type": "SECONDARY", "title": "Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose", "description": "FEV1 was measured on Day 14 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.", "populationDescription": "The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. Observed data only.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Day 14, pre-dose, 5, 20 and 30 minutes, 1, 2, 3, and 4 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days."}, {"id": "OG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "64"}, {"groupId": "OG003", "value": "69"}, {"groupId": "OG004", "value": "62"}, {"groupId": "OG005", "value": "59"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.670", "spread": "0.0419"}, {"groupId": "OG001", "value": "2.698", "spread": "0.0400"}, {"groupId": "OG002", "value": "2.772", "spread": "0.0411"}, {"groupId": "OG003", "value": "2.786", "spread": "0.0393"}, {"groupId": "OG004", "value": "2.821", "spread": "0.0418"}, {"groupId": "OG005", "value": "2.565", "spread": "0.0426"}]}]}]}, {"type": "SECONDARY", "title": "The Mean Change From Baseline to 24 Hour Post-dose (Trough) Forced Expiratory Volume in 1 Second (FEV1) on Day 1", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Change from baseline to 24 hour post dose trough FEV1 after 1 day of treatment was analyzed using Analysis of Covariance (ANCOVA) adjusting for treatment and region with baseline FEV1 as a covariate.", "populationDescription": "The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. The analysis only includes patients with non-missing data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Day 1 Baseline (prior to first dose) and 24 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days."}, {"id": "OG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "64"}, {"groupId": "OG003", "value": "69"}, {"groupId": "OG004", "value": "63"}, {"groupId": "OG005", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.054", "spread": "0.0347"}, {"groupId": "OG001", "value": "0.081", "spread": "0.0326"}, {"groupId": "OG002", "value": "0.143", "spread": "0.0339"}, {"groupId": "OG003", "value": "0.141", "spread": "0.0326"}, {"groupId": "OG004", "value": "0.155", "spread": "0.0341"}, {"groupId": "OG005", "value": "0.010", "spread": "0.0344"}]}]}]}, {"type": "SECONDARY", "title": "Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) Between Baseline (Predose) and 4 Hours Post-dose on Day 1", "description": "FEV1 was measured on Day 1 pre-dose and up to 4 hours post-dose. The Area Under the Curve (AUC) for FEV1 was analyzed using Analysis of Covariance adjusting for treatment and region with baseline FEV1 as a covariate.", "populationDescription": "The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. Observed data only.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "Day 1, pre-dose, 5, 20 and 30 minutes, 1, 2, 3, and 4 hours post-dose.", "groups": [{"id": "OG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days."}, {"id": "OG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "65"}, {"groupId": "OG003", "value": "71"}, {"groupId": "OG004", "value": "64"}, {"groupId": "OG005", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.668", "spread": "0.0281"}, {"groupId": "OG001", "value": "2.687", "spread": "0.0264"}, {"groupId": "OG002", "value": "2.726", "spread": "0.0272"}, {"groupId": "OG003", "value": "2.753", "spread": "0.0259"}, {"groupId": "OG004", "value": "2.832", "spread": "0.0274"}, {"groupId": "OG005", "value": "2.547", "spread": "0.0279"}]}]}]}, {"type": "SECONDARY", "title": "Time to Peak Forced Expiratory Volume in 1 Second (FEV1) on Day 1 and Day 14", "description": "FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Time to peak FEV1 is calculated in minutes from the time of inhalation of study drug to the time of the peak FEV1, which is taken as the maximum FEV1 recorded post-dose.", "populationDescription": "The intent-to-treat population (ITT) population consisted of all randomized patients who had a baseline and at least one post-dose FEV1 measurement. The analysis only includes patients with non-missing data, indicated by \"N\".", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "minutes", "timeFrame": "Day 1 and Day 14 measured pre-dose and up to 4 hours post-dose", "groups": [{"id": "OG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days."}, {"id": "OG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "65"}, {"groupId": "OG003", "value": "72"}, {"groupId": "OG004", "value": "64"}, {"groupId": "OG005", "value": "62"}]}], "classes": [{"title": "Day 1 [N=61, 68, 65, 71, 64, 62]", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.0", "spread": "83.02"}, {"groupId": "OG001", "value": "109.6", "spread": "81.09"}, {"groupId": "OG002", "value": "119.0", "spread": "81.64"}, {"groupId": "OG003", "value": "116.2", "spread": "75.50"}, {"groupId": "OG004", "value": "105.6", "spread": "70.64"}, {"groupId": "OG005", "value": "90.5", "spread": "82.46"}]}]}, {"title": "Day 14 [N=61, 66, 64, 70, 62, 59]", "categories": [{"measurements": [{"groupId": "OG000", "value": "103.8", "spread": "86.67"}, {"groupId": "OG001", "value": "118.7", "spread": "88.42"}, {"groupId": "OG002", "value": "96.7", "spread": "70.65"}, {"groupId": "OG003", "value": "114.0", "spread": "76.41"}, {"groupId": "OG004", "value": "114.6", "spread": "71.64"}, {"groupId": "OG005", "value": "80.4", "spread": "76.92"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning and Evening Peak Expiratory Flow", "description": "The Peak Expiratory Flow (PEF) rate is the maximal rate that a person can exhale during a short maximal expiratory effort after fully inhaling. Participants measured their PEF using a peak flow meter and recorded measurements in a diary every morning and evening during the study, prior to taking study medication. Change from baseline is the difference between the mean baseline PEF recorded during the screening period until the first day of treatment, and the overall mean PEF from Days 1 to 14.", "populationDescription": "Intent to treat population. The analysis only includes patients with non-missing data, indicated by \"N\".", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters/minute", "timeFrame": "Baseline (recorded during the screening period) and Days 1-14 (treatment period)", "groups": [{"id": "OG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days."}, {"id": "OG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "65"}, {"groupId": "OG003", "value": "72"}, {"groupId": "OG004", "value": "64"}, {"groupId": "OG005", "value": "62"}]}], "classes": [{"title": "Morning [N=56, 61, 53, 63, 57, 48]", "categories": [{"measurements": [{"groupId": "OG000", "value": "18.7", "spread": "29.28"}, {"groupId": "OG001", "value": "17.2", "spread": "34.07"}, {"groupId": "OG002", "value": "25.7", "spread": "38.37"}, {"groupId": "OG003", "value": "25.8", "spread": "47.36"}, {"groupId": "OG004", "value": "25.2", "spread": "38.28"}, {"groupId": "OG005", "value": "-4.3", "spread": "43.00"}]}]}, {"title": "Evening [N=56, 58, 54, 59, 55, 47]", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.9", "spread": "36.92"}, {"groupId": "OG001", "value": "4.2", "spread": "37.82"}, {"groupId": "OG002", "value": "18.4", "spread": "36.70"}, {"groupId": "OG003", "value": "25.8", "spread": "38.07"}, {"groupId": "OG004", "value": "26.2", "spread": "35.01"}, {"groupId": "OG005", "value": "-11.4", "spread": "50.73"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Using Rescue Medication", "description": "Participants recorded the use of rescue medications (salbutamol/albuterol) for treatment of asthma symptoms twice a day in a diary during the 14 days of the treatment period.", "populationDescription": "Intent to treat", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Over 14 days", "groups": [{"id": "OG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}, {"id": "OG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days."}, {"id": "OG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "65"}, {"groupId": "OG003", "value": "72"}, {"groupId": "OG004", "value": "64"}, {"groupId": "OG005", "value": "62"}]}], "classes": [{"title": "Night", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "36"}, {"groupId": "OG003", "value": "34"}, {"groupId": "OG004", "value": "31"}, {"groupId": "OG005", "value": "40"}]}]}, {"title": "Day", "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "43"}, {"groupId": "OG002", "value": "28"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "30"}, {"groupId": "OG005", "value": "39"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Indacaterol 62.5 \u03bcg", "description": "Indacaterol 62.5 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 61, "otherNumAffected": 2, "otherNumAtRisk": 61}, {"id": "EG001", "title": "Indacaterol 125 \u03bcg", "description": "Indacaterol 125 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 68, "otherNumAffected": 2, "otherNumAtRisk": 68}, {"id": "EG002", "title": "Indacaterol 250 \u03bcg", "description": "Indacaterol 250 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 65, "otherNumAffected": 4, "otherNumAtRisk": 65}, {"id": "EG003", "title": "Indacaterol 500 \u03bcg", "description": "Indacaterol 500 \u03bcg delivered by the TWISTHALER\u00ae device once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 72, "otherNumAffected": 8, "otherNumAtRisk": 72}, {"id": "EG004", "title": "Formoterol", "description": "Formoterol 12 \u03bcg delivered by the AEROLIZER\u00ae device twice a day and placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day for 14 days.", "seriousNumAffected": 0, "seriousNumAtRisk": 64, "otherNumAffected": 0, "otherNumAtRisk": 64}, {"id": "EG005", "title": "Placebo", "description": "Placebo to indacaterol (placebo TWISTHALER\u00ae device) once a day and placebo to formoterol (placebo AEROLIZER\u00ae device) twice a day for 14 days.", "seriousNumAffected": 1, "seriousNumAtRisk": 62, "otherNumAffected": 1, "otherNumAtRisk": 62}], "seriousEvents": [{"term": "Asthmatic crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 64}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 62}]}], "otherEvents": [{"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 68}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 72}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 64}, {"groupId": "EG005", "numAffected": 1, "numAtRisk": 62}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}